Suxia Geng
Overview
Explore the profile of Suxia Geng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li C, Xiao M, Geng S, Wang Y, Zeng L, Lai P, et al.
Front Immunol
. 2024 May;
15:1405249.
PMID: 38742110
Introduction: Exploring monocytes' roles within the tumor microenvironment is crucial for crafting targeted cancer treatments. Methods: This study unveils a novel methodology utilizing four 20-color flow cytometry panels for comprehensive...
2.
Li C, Deng C, Wu P, Liu K, Huang X, Li M, et al.
Clin Transl Sci
. 2023 Dec;
17(1):e13711.
PMID: 38129985
Chronic myelomonocytic leukemia (CMML) treatment remains a pressing clinical challenge. We conducted a retrospective analysis on 52 CMML cases, exploring the effectiveness of combining venetoclax (Vene) with hypomethylating agents (HMAs)....
3.
Chen X, Li C, Wang Y, Geng S, Xiao M, Zeng L, et al.
Hematology
. 2023 Dec;
28(1):2288475.
PMID: 38038045
This study delves into the emerging role of ferroptosis in Myelodysplastic Neoplasms (MDS) and aims to identify a prognostic ferroptosis-related gene signature for MDS. Utilizing RNA-seq data and clinical information...
4.
Chen X, Liu B, Li C, Wang Y, Geng S, Du X, et al.
Int Immunopharmacol
. 2023 Sep;
124(Pt A):110890.
PMID: 37688914
While The World Health Organization (WHO) has announced that COVID-19 is no longer a public health emergency of international concern(PHEIC), the risk of reinfection and new emerging variants still makes...
5.
Xu R, Wu M, Wang Y, Li C, Zeng L, Wang Y, et al.
Mol Med
. 2023 Apr;
29(1):59.
PMID: 37098464
Background: Myofibroblasts (MFB), one of the major effectors of pathologic fibrosis, mainly derived from the activation of fibroblast to myofibroblast transition (FMT). Although MFBs were historically considered terminally differentiated cells,...
6.
Chen X, Wang Y, Huang X, Geng S, Li C, Zeng L, et al.
Int Immunopharmacol
. 2023 Feb;
117:109746.
PMID: 36827923
Background: Chronic graft-versus-host disease (cGVHD) is the most common cause of non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). CD4 follicular helper T (Tfh) cells, specialized providers of...
7.
Zhang L, Zhou L, Wang Y, Li C, Liao P, Zhong L, et al.
Front Oncol
. 2022 Nov;
12:1057153.
PMID: 36408189
Identifying subgroups of T-cell acute lymphoblastic leukemia (T-ALL) with poor survival will significantly influence patient treatment options and improve patient survival expectations. Current efforts to predict T-ALL survival expectations in...
8.
Wang Y, Huang L, Huang T, Geng S, Chen X, Huang X, et al.
Front Microbiol
. 2022 Sep;
13:813576.
PMID: 36160244
Introduction: Dysbiosis of gut bacteria has been discovered in a large number of autoimmune diseases. However, the influence of the gut bacteria in the mice model of chronic sclerodermatous graft-versus-host...
9.
Geng S, Xu R, Huang X, Li M, Deng C, Lai P, et al.
Front Immunol
. 2022 Aug;
13:950134.
PMID: 36003379
Hypomethylating agents (HMAs) are widely used in patients with higher-risk MDS not eligible for stem cell transplantation. However, the general response rate by HMAs is lesser than 50% in MDS...
10.
Lai P, Chen X, Wang Y, Wang J, Zhang Y, Geng S, et al.
J Hematol Oncol
. 2022 May;
15(1):68.
PMID: 35597971
Although chimeric antigen receptor (CAR)-modified adoptive T cell therapy is a promising immunotherapy for hematological malignancies, the efficacy improvement in relapsed/refractory acute lymphoblastic leukemia (ALL) with extramedullary infiltration and in...